Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate - LY-CoV555.
LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) that targets the spikes of the proteins of SARS-CoV-2. So far, COVID-19 has taken the lives of more than 372,000 people globally.
The antibody was developed by Lilly after the successful identification of it through the AbCellera’s rapid artificial intelligence-based pandemic response platform from one of the US patients who managed to recover from the COVID.
The antibody blocks the entry and linking of the viral particles to human cells and prevents the disease. S...
